Hypoglycemia: From the Laboratory to the Clinic
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
Hypoglycemia is the major, and most feared, complication of the pharmacological therapies for diabetes. In health, hypoglycemia sufficient to cause clinically relevant impairment of cognitive function or cardiac rhythm is prevented by highly efficient counterregulatory mechanisms that culminate in restoration of circulating glucose concentrations. In the accompanying article, McCrimmon (1) has summarized our current understanding of how these mechanisms may be initiated and coordinated by central glucose sensing, described the possible molecular mechanisms of neuronal glucose sensing, and alluded to the defective performance of these mechanisms in insulin-treated diabetes. The principle clinical correlate of defective brain glucose sensing in diabetes is the change in the patient's awareness of the plasma glucose concentration. The clinical phenomenon of loss of awareness of hypoglycemia, and its associated increase in risk of severe hypoglycemia, is accompanied by measurable defects in the counterregulatory stress responses attributed at least in part to failure of central glucose sensing. As McCrimmon explains, the main determinant of the plasma glucose concentrations at which the brain responds actively to hypoglycemia appears to be the recent antecedent glucose exposure. Thus, people accustomed to chronic hyperglycemia may activate symptomatic stress responses as the glucose concentration falls within the physiological range—a barrier for some to tighten glucose control effectively. More extensively explored is the phenomenon of hypoglycemia unawareness, in which the body only mounts a protective counterregulatory response to falling blood glucose at glucose concentrations well below the physiologic norm. Added to the failure of glucagon responses to hypoglycemia that occurs early in type 1 diabetes, such additional counterregulatory failure may leave the patient symptom free and defenseless until plasma glucose concentrations are insufficient to support normal higher brain function. Confusion becomes the first sign of the hypoglycemia, and severe episodes (those in which the person is rendered incapable of self-treatment) ensue. In …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous glucose monitoring and intensive treatment of type 1 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0805017 · Cited by 1,559
Defining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
Heller, S. R., & Cryer, P. E. (1991) · Diabetes · doi:10.2337/diab.40.2.223 · Cited by 531
Hypoglycaemia in Type 2 diabetes
Amiel, S. A., Dixon, T., Mann, R., & Jameson, K. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2007.02341.x · Cited by 472
Self-citationBolli, G., Feo, P. D., Compagnucci, P., Cartechini, M. G., Angeletti, G., Santeusanio, F., Brunetti, P., & Gerich, J. E. (1983) · Diabetes · doi:10.2337/diab.32.2.134 · Cited by 433
Effect of intensive insulin therapy on glycemic thresholds for counterregulatory hormone release.
Amiel, S. A., Sherwin, R. S., Simonson, D. C., & Tamborlane, W. V. (1988) · Diabetes · doi:10.2337/diab.37.7.901 · Cited by 393
Self-citationWhite, N. H., Skor, D. A., Cryer, P. E., Levandoski, L. A., Bier, D. M., & Santiago, J. V. (1983) · New England Journal of Medicine · doi:10.1056/nejm198303033080903 · Cited by 391 · cited 1×
“(13) used failure to counterregulate during insulin infusion as a successful predictor of future problematic hypoglycemia in subsequent application of intensified insulin therapy.”
MethodHorvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005613.pub3 · Cited by 366
Amiel, S. A., Tamborlane, W. V., Simonson, D. C., & Sherwin, R. S. (1987) · New England Journal of Medicine · doi:10.1056/nejm198705283162205 · Cited by 309
Self-citation(1995) · Diabetes Care · doi:10.2337/diacare.18.11.1415 · Cited by 305
Accurso, A., Bernstein, R. K., Dahlqvist, A., Draznin, B., Feinman, R. D., Fine, E. J., Gleed, A., Jacobs, D. B., Larson, G., Lustig, R. H., et al. (2008) · Nutrition & Metabolism · doi:10.1186/1743-7075-5-9 · Cited by 263
Blood Glucose Awareness Training (BGAT-2)
Cox, D. J., Gonder-Frederick, L., Polonsky, W., Schlundt, D., Kovatchev, B., & Clarke, W. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.637 · Cited by 235
Sämann, A., Mühlhauser, I., Bender, R., Kloos, C., & Müller, U. A. (2005) · Diabetologia · doi:10.1007/s00125-005-1905-1 · Cited by 226
Effects of differing antecedent hypoglycemia on subsequent counterregulation in normal humans
Davis, S. N., Shavers, C., Mosqueda-Garcia, R., & Costa, F. (1997) · Diabetes · doi:10.2337/diab.46.8.1328 · Cited by 183
Activation of human medial prefrontal cortex during autonomic responses to hypoglycemia
Teves, D., Videen, T. O., Cryer, P. E., & Powers, W. J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307048101 · Cited by 138 · cited 1×
“(22) showed an increase in regional brain perfusion using [15O]-H2O water positron emission tomography (PET) in anterior cingulate cortex and thalamus during hypoglycemia in healthy volunteers.”
Prediction of Severe Hypoglycemia
Cox, D. J., Gonder-Frederick, L., Ritterband, L., Clarke, W., & Kovatchev, B. P. (2007) · Diabetes Care · doi:10.2337/dc06-1386 · Cited by 129
Mühlhauser, I., Overmann, H., Bender, R., Bott, U., & Berger, M. (1998) · Diabetologia · doi:10.1007/s001250051065 · Cited by 117 · cited 1×
“One of the best predictors is an absence of Cpeptide; another even stronger predictor is having a history of severe hypoglycemia (4).”
BackgroundMaran, A., Lomas, J., Macdonald, I. A., & Amiel, S. A. (1995) · Diabetologia · doi:10.1007/bf00400601 · Cited by 102 · cited 1×
“8 –3 mmol/l is the arterialised plasma glucose concentration in clampinduced experimental hypoglycemia at which cognitive function first becomes detectable (as a deterioration in complex reaction time) (43).”
BackgroundSelf-citationDavis, S. N., Mann, S., Galassetti, P., Neill, R. A., Tate, D., Ertl, A. C., & Costa, F. (2000) · Diabetes · doi:10.2337/diabetes.49.11.1897 · Cited by 100 · cited 1×
“3 mmol/l) have more extreme effects on the catecholamine, pancreatic polypeptide, growth hormone, endogenous glucose production, and lipolytic responses to hypoglycemia, although at least 30 min of exposure to lower glucose concentrations is required to affect subjective awareness, at least in experimental models (18).”
BackgroundDavis, S. N., Mann, S., Briscoe, V. J., Ertl, A. C., & Tate, D. B. (2009) · Diabetes · doi:10.2337/db08-1230 · Cited by 74
The effect of modafinil on counter-regulatory and cognitive responses to hypoglycaemia
Smith, D., Pernet, A., Rosenthal, J. M., Bingham, E. M., Reid, H., Macdonald, I. A., & Amiel, S. A. (2004) · Diabetologia · doi:10.1007/s00125-004-1513-5 · Cited by 31 · cited 1×
“In a single-dose healthy volunteer study, modafinil, which diminishes brain GABA levels by noradrenergic stimulation of serotonergic neurons, enhanced heart rate responses and symptom scores during hypoglycemia and supported some aspects of cognitive function (53).”
BackgroundSelf-citationBingham, E., Hopkins, D., Pernet, A., Reid, H., Macdonald, I. A., & Amiel, S. A. (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.00922.x · Cited by 22 · cited 1×
“In a human study, however, a single dose of the sulfonylurea glibenclamide had equivocal effect on normal glucose counterregulatory hormone release but diminished the cognitive dysfunction seen with the hypoglycemia, compatible with the presence of sulfonylurea receptors in the cortex (52).”
BackgroundSelf-citationDEGALAN, B., TACK, C., LENDERS, J., LUTTERMAN, J., & SMITS, P. (2003) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(03)00093-6 · Cited by 12
Cited by
(2011) · PubMed · Cited by 187
Restoration of Self-Awareness of Hypoglycemia in Adults With Long-Standing Type 1 Diabetes
Leelarathna, L., Little, S. A., Walkinshaw, E., Tan, H. K., Lubina-Solomon, A., Kumareswaran, K., Lane, A. P., Chadwick, T., Marshall, S. M., Speight, J., et al. (2013) · Diabetes Care · doi:10.2337/dc13-1004 · Cited by 56
Acute hypoglycemia causes depressive-like behaviors in mice
Park, M. J., Yoo, S. W., Choe, B. S., Dantzer, R., & Freund, G. G. (2012) · Metabolism · doi:10.1016/j.metabol.2011.06.013 · Cited by 41
“Hypoglycemia triggers a robust activation of the autonomic nervous system (11,12) with marked changes in circulating (13) and brain-based catecholamines (14).”
BackgroundGhandi, K., Pieri, B., Dornhorst, A., & Hussain, S. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00965-0 · Cited by 34
Metadata
- Authors
- Amiel, S. A.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2009-08-01
- Volume
- 32
- Issue
- 8
- Pages
- 1364-1371
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2128502852
- Cited by
- 44
- References
- 23
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.